Ondansetron

Study Reference
Anderka, 2012

Anderka M Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2012;94:22-30

Andersen, 2013

Andersen JT Ondansetron use in early pregnancy and the risk of congenital malformations – a registry based nationwide cohort study Abstract. Pharmacoepidemiol Drug Saf. 2013;22(Suppl 1):13–14

Bérard, 2019

Bérard New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. J Clin Epidemiol 2019; 116:39-48

Clements, 2015

Clements CC Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry 2015;20:727-34

Colvin, 2013

Colvin L Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int 2013;2013:909860

Danielsson, 2014

Danielsson B Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol 2014;50:134-7

Einarson (Control exposed to other antiemetics), 2004

Einarson A The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940-3

Einarson (Unexposed control), 2004

Einarson A The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940-3

Fejzo, 2015

Fejzo MS Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 2015;189:79-84

Fejzo (Mainly exposed to other treatements, sick), 2016

Fejzo MS Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol 2016;62:87-91

Fejzo (Unexposed control, disease free), 2016

Fejzo MS Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol 2016;62:87-91

Huybrechts, 2019

Huybrechts Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations JAMA Published online November 15, 2019

Huybrechts (Control exposed to other treatment), 2018

Huybrechts KF Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA 2018;320:2429-2437

Huybrechts (Unexposed control), 2018

Huybrechts KF Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA 2018;320:2429-2437

Lemon, 2019

Lemon Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. Int J Epidemiol 2019; :

Lind (Controls exposed to metoclopramide, sick), 2013

Lind Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. Pharmacoepidemiol Drug Saf 2013; 22:783-93

Lind (Controls unexposed, NOS), 2013

Lind Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. Pharmacoepidemiol Drug Saf 2013; 22:783-93

Marciniak, 2015

Marciniak A The influence of intravenous ondansetron on maternal blood haemodynamics after spinal anaesthesia for caesarean section: a double-blind, placebo-controlled study. Ginekol Pol 2015;86:461-7

Oofuvong, 2018

Oofuvong Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial. BMC Anesthesiol 2018; 18:105

Ozdemirci, 2014

Ozdemirci S The Safety of Ondansetron and Chlorpromazine for Hyperemesis Gravidarum in First Trimester Pregnancy Gynecol Obstet Reprod Med 2014;20:81-84

Parker, BDS study, 2018

Parker SE Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol 2018;132:385-394

Parker, NBDPS study, 2018

Parker SE Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol 2018;132:385-394

Pasternak, 2013

Pasternak B Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med 2013;368:814-23

Shahraki, 2016

Shahraki Comparing Neonatal Outcome Following the Use of Ondansetron versus Vitamin B6 in Pregnant Females with Morning Sickness: A Randomized Clinical Trial J Compr Ped. 2016;7(4):e37081.

Werler, 2014

Werler Medication use in pregnancy in relation to the risk of isolated clubfoot in offspring. Am. J. Epidemiol. 2014; 180:86-93

Zambelli-Weiner (Unexposed control, NOS), 2019

Zambelli-Weiner A First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol 2019;83:14-20

Zambelli-Weiner (Unexposed control, sick), 2019

Zambelli-Weiner A First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol 2019;83:14-20